• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用二分类生存数据为贝叶斯无缝 II/III 期临床试验构建先验分布。

Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.

机构信息

Universitè Paris Citè, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, Paris, France.

Inria, HeKA, Paris, France.

出版信息

Stat Methods Med Res. 2023 May;32(5):963-977. doi: 10.1177/09622802231160554. Epub 2023 Mar 15.

DOI:10.1177/09622802231160554
PMID:36919403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10521165/
Abstract

Master protocol designs allow for simultaneous comparison of multiple treatments or disease subgroups. Master protocols can also be designed as seamless studies, in which two or more clinical phases are considered within the same trial. They can be divided into two categories: operationally seamless, in which the two phases are separated into two independent studies, and inferentially seamless, in which the interim analysis is considered an adaptation of the study. Bayesian designs are scarcely studied. Our aim is to propose and compare Bayesian operationally seamless Phase II/III designs using a binary endpoint for the first stage and a time-to-event endpoint for the second stage. At the end of Phase II, arm selection is based on posterior (futility) and predictive (selection) probabilities. The results of the first phase are then incorporated into prior distributions of a time-to-event model. Simulation studies showed that Bayesian operationally seamless designs can approach the inferentially seamless counterpart, allowing for an increasing simulated power with respect to the operationally frequentist design.

摘要

主方案设计允许同时比较多种治疗方法或疾病亚组。主方案也可以设计为无缝研究,其中两个或更多的临床阶段被认为是在同一个试验内。它们可以分为两类:操作上的无缝,其中两个阶段被分成两个独立的研究,以及推理上的无缝,其中中期分析被认为是研究的一种适应。贝叶斯设计几乎没有被研究过。我们的目的是提出并比较使用二项终点作为第一阶段和时间事件终点作为第二阶段的贝叶斯操作上无缝的二期/三期设计。在二期结束时,臂的选择基于后验(无效)和预测(选择)概率。然后,第一阶段的结果被纳入时间事件模型的先验分布中。模拟研究表明,贝叶斯操作上的无缝设计可以接近推理上的无缝设计,允许相对于操作上的频率设计增加模拟功效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/e0457e4ed022/10.1177_09622802231160554-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/ebe9a4e693fc/10.1177_09622802231160554-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/dc7a3c86f465/10.1177_09622802231160554-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/37ba9ba74181/10.1177_09622802231160554-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/345fb16b8633/10.1177_09622802231160554-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/e0457e4ed022/10.1177_09622802231160554-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/ebe9a4e693fc/10.1177_09622802231160554-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/dc7a3c86f465/10.1177_09622802231160554-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/37ba9ba74181/10.1177_09622802231160554-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/345fb16b8633/10.1177_09622802231160554-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1b/10521165/e0457e4ed022/10.1177_09622802231160554-fig5.jpg

相似文献

1
Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.使用二分类生存数据为贝叶斯无缝 II/III 期临床试验构建先验分布。
Stat Methods Med Res. 2023 May;32(5):963-977. doi: 10.1177/09622802231160554. Epub 2023 Mar 15.
2
Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.在终点为直至某个指定时间点的生存情况的无缝II/III期试验中用于中期适应性调整的贝叶斯预测能力。
Stat Med. 2007 Nov 30;26(27):4925-38. doi: 10.1002/sim.2957.
3
Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.贝叶斯分组序贯设计在三期急诊医学试验中的应用:以 PARAMEDIC2 试验为例
Trials. 2020 Jan 14;21(1):84. doi: 10.1186/s13063-019-4024-x.
4
A randomized Bayesian optimal phase II design with binary endpoint.一种具有二分类结局的随机化贝叶斯最优 II 期设计。
J Biopharm Stat. 2023 Mar;33(2):151-166. doi: 10.1080/10543406.2022.2094938. Epub 2022 Jul 6.
5
Bayesian optimal phase II clinical trial design with time-to-event endpoint.贝叶斯最优设计的Ⅱ期临床试验设计,以时间为终点事件。
Pharm Stat. 2020 Nov;19(6):776-786. doi: 10.1002/pst.2030. Epub 2020 Jun 10.
6
Interpreting a Bayesian phase II futility clinical trial.解读贝叶斯二期无效临床试验。
Trials. 2022 Nov 22;23(1):953. doi: 10.1186/s13063-022-06877-7.
7
The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints.双臂II期临床试验设计中具有多个事件发生时间终点的贝叶斯监测中的胜率方法
Stat Med. 2024 Dec 30;43(30):5922-5934. doi: 10.1002/sim.10282. Epub 2024 Nov 25.
8
DOD-SSR: An Adaptive Seamless Phase II/III Design With Dose Optimization Decision and Sample Size Re-estimation.国防部-无缝过渡研究:一种具有剂量优化决策和样本量重新估计的适应性无缝II/III期设计
Stat Med. 2025 Feb 28;44(5):e70014. doi: 10.1002/sim.70014.
9
Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.贝叶斯单臂试验序贯监测:基于二分类数据的无效性规则比较。
Int J Environ Res Public Health. 2021 Aug 20;18(16):8816. doi: 10.3390/ijerph18168816.
10
Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.多臂临床试验中的适应性治疗分配和选择:贝叶斯视角。
BMC Med Res Methodol. 2022 Feb 20;22(1):50. doi: 10.1186/s12874-022-01526-8.

本文引用的文献

1
Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?受 COVID-19 大流行影响的临床试验:适应性设计能否拯救局面?
Stat Biopharm Res. 2020 Aug 19;12(4):461-477. doi: 10.1080/19466315.2020.1799857.
2
Predictively consistent prior effective sample sizes.可预测一致性先验有效样本量。
Biometrics. 2020 Jun;76(2):578-587. doi: 10.1111/biom.13252. Epub 2020 Apr 6.
3
Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R.
自适应无缝临床试验,使用早期结果进行治疗或亚组选择:方法、模拟模型及其在 R 中的实现。
Biom J. 2020 Sep;62(5):1264-1283. doi: 10.1002/bimj.201900020. Epub 2020 Mar 2.
4
An adaptive power prior for sequential clinical trials - Application to bridging studies.序贯临床试验的自适应幂先验——在桥接研究中的应用。
Stat Methods Med Res. 2020 Aug;29(8):2282-2294. doi: 10.1177/0962280219886609. Epub 2019 Nov 15.
5
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.系统评价篮子试验、伞式试验和平台试验:主方案的全景分析。
Trials. 2019 Sep 18;20(1):572. doi: 10.1186/s13063-019-3664-1.
6
A Bayesian non-inferiority approach using experts' margin elicitation - application to the monitoring of safety events.一种使用专家边际推断的贝叶斯非劣效性方法 - 在安全事件监测中的应用。
BMC Med Res Methodol. 2019 Sep 18;19(1):187. doi: 10.1186/s12874-019-0826-5.
7
Quantification of prior impact in terms of effective current sample size.根据有效当前样本量来量化先前的影响。
Biometrics. 2020 Mar;76(1):326-336. doi: 10.1111/biom.13124. Epub 2019 Sep 13.
8
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III.一种允许在III期进行剂量重新优化的I-II/III期混合临床试验设计。
Biometrics. 2019 Jun;75(2):371-381. doi: 10.1111/biom.12994. Epub 2019 Apr 3.
9
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.用于研究多种疗法、多种疾病或两者兼有的主方案。
N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062.
10
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.临床研究中的统计学争议:篮子试验、伞式试验和其他主方案:综述和实例。
Ann Oncol. 2017 Jan 1;28(1):34-43. doi: 10.1093/annonc/mdw413.